Park Square Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.25K Buy
+2
New +$1.36K 0.01% 192
2026
Q1
Sell
-5
Closed -$3.56K 307
2025
Q4
$3.56K Buy
+5
New +$3.4K 0.02% 200
2025
Q3
Sell
-185
Closed -$97.1K 807
2025
Q2
$97.1K Sell
185
-101
-35% -$56.4K 0.07% 204
2025
Q1
$181K Buy
286
+208
+267% +$143K 0.14% 96
2024
Q4
$55.6K Buy
+78
New +$65.5K 0.04% 252

Other funds holding REGN

Park Square Financial Group's REGN Position: Q2 2026 in Review

Park Square Financial Group opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 2 shares worth $1.25K. The stake represents 0.01% of the portfolio and ranks #192 among its holdings. This is a return to the name: Park Square Financial Group previously reported a position in REGN as recently as Q4 2025.

Park Square Financial Group first reported a position in REGN in Q4 2024 and has held it in 5 quarters since. The position peaked at $181K in Q1 2025. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Park Square Financial Group held 2 shares of Regeneron Pharmaceuticals worth $1.25K as of Q2 2026.
  • Regeneron Pharmaceuticals was a new Park Square Financial Group position in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.01% of Park Square Financial Group's portfolio in Q2 2026, its #192 holding.
  • Park Square Financial Group first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Park Square Financial Group's Regeneron Pharmaceuticals position peaked at $181K in Q1 2025.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Park Square Financial Group's 13F filing for Q2 2026, filed 31 Jul 2026.